Senores Steps Up: IPO Power Fuels Abbreviated New Drug Applications (ANDA) Acquisition Bonanza

Senores Pharmaceuticals Limited (SPL) has taken an important step to strengthen its position in the US generics market by acquiring a portfolio of 14 Abbreviated New Drug Applications (ANDAs) from Dr. Reddy's Laboratories. The acquisition, which is financed wholly by proceeds from SPL's recent Initial Public Offering (IPO), will enhance the company's product portfolios and market coverage in line with its strategic growth goals.

 

Key Points

 

Acquisition Overview

SPL, through its US subsidiary, entered into agreements to buy 14 ANDAs of Dr. Reddy's Laboratories and its subsidiaries.

 

The portfolio includes 13 ANDAs that are already approved by the US Food and Drug Administration (USFDA) and 1 ANDA which is under approval by USFDA.

 

Financial and Market Impact

The addressable market opportunity for these ANDAs in the US has been estimated at around USD 421 million (based on IQVIA, MAT December 2024) and up to USD 1.13 billion (based on Symphony, MAT September 2024).

 

The acquisition is being financed by the entire proceeds of SPL's IPO, as per its goals defined under its Red Herring Prospectus.

 

Strategic Rationale

The products picked up cover numerous therapeutic categories, both general category drugs and controlled substances, in recognition of increasing demand in these categories.

 

These products are distributable through various channels with important needs in specialty clinics, retail, and government.

 

This acquisition meaningfully expands SPL's US product portfolio and enhances value in other regulated and semi-regulated markets around the world.

 

Leadership Commentary

We are pleased to announce the acquisition of a basket of products from Dr Reddy's. It crosses over multiple therapeutic categories with increasing consumption. The basket includes controlled drugs and general category of products. These drugs can be channelled through diverse/multiple channels, with sizeable requirements in government, retail and specialty clinics.". This product portfolio substantially enhances our product portfolio in the US, and also it is of substantial value in other regulated and semi-regulated markets of the world.

 

Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited

 

Market Response

After the announcement, SPL's share price registered a rise, indicating positive investor sentiment towards the company's growth opportunity in the US market.

 

Sources: senorespharma, Economic Times, Senores Pharmaceuticals Media Release, ETPharma, Pharmabiz, Angel One